Cargando…

Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis

OBJECTIVE: Chemotherapy is one of the commonly used therapies for advanced gastric cancer. In this study, we performed a network meta-analysis on the efficacy and safety of common treatments to give evidences of their relative benefits. RESULTS: 32 trials with 8550 patients and 20 regimens were incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jinping, Ren, Zheng, Sun, Xinfang, Hou, Hongtao, Li, Ke, Ge, Quanxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503642/
https://www.ncbi.nlm.nih.gov/pubmed/28562333
http://dx.doi.org/10.18632/oncotarget.17784
_version_ 1783249144291262464
author Sun, Jinping
Ren, Zheng
Sun, Xinfang
Hou, Hongtao
Li, Ke
Ge, Quanxing
author_facet Sun, Jinping
Ren, Zheng
Sun, Xinfang
Hou, Hongtao
Li, Ke
Ge, Quanxing
author_sort Sun, Jinping
collection PubMed
description OBJECTIVE: Chemotherapy is one of the commonly used therapies for advanced gastric cancer. In this study, we performed a network meta-analysis on the efficacy and safety of common treatments to give evidences of their relative benefits. RESULTS: 32 trials with 8550 patients and 20 regimens were included in this study. According to the results of primary outcomes, 5-FU plus OXA, 5-FU plus DOC, CAP plus CIS, CAP plus OXA, S-1 plus OXA and S-1 plus PAC performed well in improving OS and ORR. As for the adverse events, S-1 had a safer effect than other treatments, conversely, 5-FU plus CIS ranked the last. However, there was no regimen with outstanding performances in both efficacy and safety. MATERIALS AND METHODS: Studies were searched from database and screened with criteria. The Bayesian framework based network meta-analysis was performed with software R and STATA. Overall survival (OS) and overall response rate (ORR) were considered as primary outcomes while adverse events as secondary outcomes. The outcomes were represented by hazard ratios or odd ratios with 95% corresponding credible intervals, respectively. CONCLUSIONS: The network meta-analysis suggested that 5-FU plus OXA and 5-FU plus DOC were recommended when efficacy was stressed. S-1 was safest but poorly effective. A regimen, as an excellent combination of efficacy and safety, is still waiting to be discovered.
format Online
Article
Text
id pubmed-5503642
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55036422017-07-11 Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis Sun, Jinping Ren, Zheng Sun, Xinfang Hou, Hongtao Li, Ke Ge, Quanxing Oncotarget Meta-Analysis OBJECTIVE: Chemotherapy is one of the commonly used therapies for advanced gastric cancer. In this study, we performed a network meta-analysis on the efficacy and safety of common treatments to give evidences of their relative benefits. RESULTS: 32 trials with 8550 patients and 20 regimens were included in this study. According to the results of primary outcomes, 5-FU plus OXA, 5-FU plus DOC, CAP plus CIS, CAP plus OXA, S-1 plus OXA and S-1 plus PAC performed well in improving OS and ORR. As for the adverse events, S-1 had a safer effect than other treatments, conversely, 5-FU plus CIS ranked the last. However, there was no regimen with outstanding performances in both efficacy and safety. MATERIALS AND METHODS: Studies were searched from database and screened with criteria. The Bayesian framework based network meta-analysis was performed with software R and STATA. Overall survival (OS) and overall response rate (ORR) were considered as primary outcomes while adverse events as secondary outcomes. The outcomes were represented by hazard ratios or odd ratios with 95% corresponding credible intervals, respectively. CONCLUSIONS: The network meta-analysis suggested that 5-FU plus OXA and 5-FU plus DOC were recommended when efficacy was stressed. S-1 was safest but poorly effective. A regimen, as an excellent combination of efficacy and safety, is still waiting to be discovered. Impact Journals LLC 2017-05-11 /pmc/articles/PMC5503642/ /pubmed/28562333 http://dx.doi.org/10.18632/oncotarget.17784 Text en Copyright: © 2017 Sun et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Meta-Analysis
Sun, Jinping
Ren, Zheng
Sun, Xinfang
Hou, Hongtao
Li, Ke
Ge, Quanxing
Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis
title Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis
title_full Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis
title_fullStr Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis
title_full_unstemmed Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis
title_short Efficacy and safety comparison of chemotherapies for advanced gastric cancer: A network meta-analysis
title_sort efficacy and safety comparison of chemotherapies for advanced gastric cancer: a network meta-analysis
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503642/
https://www.ncbi.nlm.nih.gov/pubmed/28562333
http://dx.doi.org/10.18632/oncotarget.17784
work_keys_str_mv AT sunjinping efficacyandsafetycomparisonofchemotherapiesforadvancedgastriccanceranetworkmetaanalysis
AT renzheng efficacyandsafetycomparisonofchemotherapiesforadvancedgastriccanceranetworkmetaanalysis
AT sunxinfang efficacyandsafetycomparisonofchemotherapiesforadvancedgastriccanceranetworkmetaanalysis
AT houhongtao efficacyandsafetycomparisonofchemotherapiesforadvancedgastriccanceranetworkmetaanalysis
AT like efficacyandsafetycomparisonofchemotherapiesforadvancedgastriccanceranetworkmetaanalysis
AT gequanxing efficacyandsafetycomparisonofchemotherapiesforadvancedgastriccanceranetworkmetaanalysis